Objective To investigate the clinical curative effect, safety and adverse reaction of Hyper-CVAD/MA regimen for T-cell lymphoma. Methods Sixteen cases with T-cell lymphoma were treated with Hyper -CVAD/MA regimen. Results The overall response rate was 75%, including 7 cases (43.8%) of complete response (CR), 5 cases (31.3%) of patial response (PR). One-year progression-free survival (PFS) was 62.5%, one-year overall survival (OS) rate was 81.3%. Adverse reactions mainly including chemotherapy-related hematologic toxicity and could be tolerated. Conclusion Hyper-CVAD/MA regimen has a satisfying short-term therapeutic effect on patients with T-cell lymphoma, the side effects can be controlled.%目的 评价Hyper-CVAD/MA方案治疗T细胞淋巴瘤的疗效、安全性和不良反应.方法 16例T细胞淋巴瘤初治患者采用Hyper-CVAD/MA方案进行化疗.化疗每约4周为1个疗程,每疗程评价疗效和不良反应.结果 经治疗后16例患者中完全缓解(CR)7例(43.8%),部分缓解(PR)5例(31.3%),有效率为75%.随访1年无进展生存(PFS)率为62.5%,1年总生存(OS)率为81.3%.不良反应主要为血液学毒性,均可耐受.结论 Hyper-CVAD/MA方案治疗T细胞淋巴瘤近期疗效满意,治疗相关不良反应易于控制.
展开▼
